Sanofi has never been one of biopharma’s leading oncology companies. Now it barely has a presence here at all, its last remaining novel late-stage cancer candidate, tusamitamab ravtansine, having failed in lung disease.
Key Takeaways
- Tusamitamab ravtansine has failed in a Phase III lung cancer trial
Tusamitamab ravtansine is an antibody-drug conjugate with a novel target: carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), a protein that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?